Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)
Based on 2 publication(s) in Google Scholar
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-10R/CD210. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) blocks IL-10R signaling. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) can be used for the researches of cancer, infection and metabolic disease, such as diabetes and malaria.
For research use only. We do not sell to patients.
- Purity : 99.08%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)
MoreAll Parasite Isoforms
More
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
IL-10R/CD210
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (0.3 mg/mouse at 1 day before infection and 0.2 mg/mouse at days 1, 4, 6 postinfection, i.p.) reduces survival rate and increases cumulative experimental cerebral malaria incidence in P. berghei ANKA infected mice models[2].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (250 μg, i.v., twice a week) improves capillary stalling and cognitive impairment in type 1 diabetes mice[3].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (1.5 mg, i.p., a single dose) reduces CD103 expression on lung-resident T cells and TGF-β1 levels in wild-type B6 mice[4].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (500 μg at day 0 and 300 μg twice a week after tumor cell injection, i.p.) reduces the lymphoma burden and reduces the intratumoral frequencies of regulatory T-cells in a syngeneic transplantation mice model[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pulmonary C. neoformans infected mice models[1]
-
Dosage:0.5 mg/dose
-
Administration:Intraperitoneally injection, 3 times for early treatment at days 3, 6, 9 and late treatment at days 15, 18, 21
-
Result:Significantly reduced pulmonary fungal CFU.
Reduced fungal clearance.
Increased lung leukocyte accumulation and total numbers of CD4+ T cells and Th17 cells.
Increased the total numbers of B cells with late treatment.
Increased IFN-γ levels.
Increased the activation of lung dendritic cells and macrophages.
Reduced central nervous system dissemination.
-
Animal Model:P. berghei ANKA infected mice models[2]
-
Dosage:0.3 mg/mouse at 1 day before infection and 0.2 mg/mouse at days 1, 4, 6 postinfection
-
Administration:Intraperitoneally injection
-
Result:Reduced survival rate and parasitemia values and increased cumulative experimental cerebral malaria incidence and CD8+ T cells.
Significantly elevated generalized parasite biomass and the numbers of brain petechial hemorrhages.
Increased IFN-γ and IL-10 levels.
Increased proportions of splenic CD4+ and CD8+ T cells expressing CD62L- and CD11a+and producing IFN-γ.
-
Animal Model:Type 1 diabetic mice models[3]
-
Dosage:250 μg
-
Administration:Intravenously injection, twice a week
-
Result:Had significantly lower density of obstructed capillaries in the forebrain or across different brain regions.
Decreased stalling rates, and increases capillary flux and capillary width.
Helped to partially normalize CBF responses and improved cognitive function.
Upregulated gene pathways involved in the regulation of reactive oxygen species and energy metabolism, and downregulated gene pathways that regulate cellular adhesion, platelet activation and atherosclerosis.
-
Animal Model:Wild-type B6 mice[4]
-
Dosage:1.5 mg
-
Administration:Intraperitoneally injection
-
Result:Reduced CD103 expression on lung-resident T cells.
Reduced TGF-β1 levels.
-
Animal Model:Myc-expressing lymphoma tumor mice models[5]
-
Dosage:500 μg at day 0 and 300 μg twice a week after tumor cell injection
-
Administration:Intraperitoneally injection
-
Result:Strongly reduced lymph node weights and the frequencies of CD19+ CD45int tumor B-cells.
Increased the lymph node frequencies of TCRα/β+ T-cells, equally affecting CD4+ and CD8+ T-cell population.
Increased TNF-α-producing and decreased FoxP3+ regulatory T-cells.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo blocking of IL-10/IL-10R signaling; in vitro blocking of IL-10R signaling; Flow cytometry;
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Immunity
An SPP1-SOCS1 pathway constrains interferon responses in tumor-associated macrophages and shapes an immunosuppressive tumor microenvironment. [Abstract]2026 Apr 27:S1074-7613(26)00141-X. PMID: 42049035 -
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Murdock BJ, et al. Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. J Immunol. 2014 Oct 15;193(8):4107-16. [Content Brief]
[2]. Claser C, et al. Host Resistance to Plasmodium-Induced Acute Immune Pathology Is Regulated by Interleukin-10 Receptor Signaling. Infect Immun. 2017 May 23;85(6):e00941-16. [Content Brief]
[3]. harma S, et al. A pathogenic role for IL-10 signalling in capillary stalling and cognitive impairment in type 1 diabetes. Nat Metab. 2024 Nov;6(11):2082-2099. [Content Brief]
[4]. Thompson EA, et al. Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-β Release. Cell Rep. 2019 Jul 30;28(5):1127-1135.e4. [Content Brief]
[5]. Stirm K, et al. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. Oncoimmunology. 2021 Nov 22;10(1):2003533. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Related Classifications
HY-P990228 Related Classifications
Powered by Bioz